Presentation Outline ICHP Annual Meeting September 13-15

650 subjects
id identified tifi d
Results
250 subjects
randomly
selected
324 encounters
evaluated l t d
Baseline Characteristics: Encounters
Encounters [n = 324] No (%)
Initial Episode 220 (67.7)
1st 1 recurrence 56 (17.3)
2nd recurrence 10 (3.1)
3rd recurrence 5 (1.5)
Reinfection 33 (10.2)
Severity [n = 324] No (%)
Mild‐moderate Mild moderate 163 (50.3)
Severe 105 (32.4)
Severe‐complicated 56 (17.3)
Mild‐moderate Treatment Regimens
Regimen [n = 163] No (%)
Metronidazole 500 mg PO q8h 66 (40.5)
Metronidazole 500 mg IV q8h 22 (13.5)
Vancomycin 125 mg PO q6h * 51 (31.3)
Metronidazole 500 mg IV q8h +
vancomycin 125 mg PO q6h
13 (8)
Other 11 (6.7)
* Appropriate depending on
subject’s history of illness.
Baseline Characteristics: Subjects
Characteristics [n = 250]
Female [no (%)] 141 (56.4)
Age [mean (SD), range] 67.83 ± 17.36 (18 – 100)
Ethnicity [no (%)]
Caucasian
African‐American
Asian
Hispanic
210 (84)
13 (5.2)
12 (4.8)
7 (2.8)
History of CDI [no (%)] 18 (7.2)
Adherence Rates
No (%)
Overall [n = 324] 137 (42.3)
Mild‐moderate [n = 163] 86 (52.8)
Severe [n = 105] 41 (39)
Severe‐complicated [n = 56] 10 (17.9) p < 0.001
Mild‐moderate Treatment Regimens
8/29/2012
3